Compare AU
Compare QPON vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Australian Bank Senior Floating Rate Bond ETF (QPON) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QPON | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 82 |
Median incremental investment | $5,000.00 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,761.30 | $1,323.41 |
Average age group | > 35 | > 35 |
Key Summary
QPON | CURE | |
|---|---|---|
Strategy | QPON.AX was created on 2017-06-01 by BetaShares. The fund's investment portfolio concentrates primarily on high yield fixed income. QPON.AX aims to track the performance of an index (before fees and expenses) that measures the performance of a portfolio of some of the largest and most liquid senior floating rate bonds issued by Australian banks. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | NATIONAL AUSTRALIA BANK LTD FRN MAR-29 (10.02 %) WESTPAC BANKING CORP FRN MAY-29 (9.98 %) WESTPAC BANKING CORP FRN JAN-29 (9.97 %) | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) |
Top 3 industries | Other (96.47 %) Communication Services (3.53 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.22 % | 0.45 % |
Key Summary
QPON | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Solactive Australian Bank Senior Floating Rate Bond Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.22 % | 0.45 % |
Price | $26.05 | $49.94 |
Size | $1.551 billion | $38.065 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.63 % | 4.24 % |
Market | ASX | ASX |
First listed date | 06/06/2017 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QPON | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 82 |
Median incremental investment | $5,000.00 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,761.30 | $1,323.41 |
Average age group | > 35 | > 35 |
Pros and Cons
QPON | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
QPON | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |